Omeros (NASDAQ:OMER) Lowered to "Sell" Rating by Wall Street Zen

Wall Street Zen lowered shares of Omeros (NASDAQ:OMER - Free Report) from a hold rating to a sell rating in a research report report published on Friday.

A number of other brokerages have also issued reports on OMER. Needham & Company LLC reaffirmed a "hold" rating on shares of Omeros in a report on Friday, May 16th. HC Wainwright assumed coverage on shares of Omeros in a research note on Tuesday, June 10th. They set a "buy" rating and a $9.00 target price for the company. Finally, D. Boral Capital reiterated a "buy" rating and issued a $36.00 price target on shares of Omeros in a research note on Tuesday, May 13th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating, three have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, Omeros currently has a consensus rating of "Moderate Buy" and a consensus price target of $18.00.

Omeros Stock Down 3.6%

NASDAQ:OMER traded down $0.12 on Friday, reaching $3.20. 1,695,129 shares of the company's stock traded hands, compared to its average volume of 711,194. The stock has a 50-day simple moving average of $4.45 and a 200-day simple moving average of $7.17. Omeros has a 12 month low of $2.97 and a 12 month high of $13.60. The firm has a market cap of $187.49 million, a PE ratio of -1.21 and a beta of 2.20.

Omeros (NASDAQ:OMER - Get Free Report) last released its earnings results on Thursday, May 15th. The biopharmaceutical company reported ($0.65) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.60) by ($0.05). On average, equities analysts anticipate that Omeros will post -3.09 earnings per share for the current year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the company. Raymond James Financial Inc. bought a new stake in Omeros in the fourth quarter worth $124,000. Price T Rowe Associates Inc. MD grew its stake in shares of Omeros by 12.5% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 39,582 shares of the biopharmaceutical company's stock worth $392,000 after buying an additional 4,401 shares in the last quarter. Cerity Partners LLC increased its holdings in shares of Omeros by 9.9% in the 4th quarter. Cerity Partners LLC now owns 28,989 shares of the biopharmaceutical company's stock worth $286,000 after buying an additional 2,600 shares during the last quarter. Quantbot Technologies LP purchased a new stake in shares of Omeros during the 4th quarter valued at about $46,000. Finally, GAMMA Investing LLC lifted its holdings in shares of Omeros by 14,486.3% in the 1st quarter. GAMMA Investing LLC now owns 7,439 shares of the biopharmaceutical company's stock valued at $61,000 after acquiring an additional 7,388 shares during the last quarter. 48.79% of the stock is currently owned by institutional investors.

Omeros Company Profile

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.